Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.
Identifieur interne : 000339 ( PubMed/Checkpoint ); précédent : 000338; suivant : 000340Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.
Auteurs : Laure Elens [Belgique] ; Loralie J. Langman [États-Unis] ; Dennis A. Hesselink [Pays-Bas] ; Stein Bergan [Norvège] ; Dirk Jan A R. Moes [Pays-Bas] ; Mariadelfina Molinaro [Italie] ; Raman Venkataramanan [États-Unis] ; Florian Lemaitre [France]Source :
- Therapeutic drug monitoring [ 1536-3694 ] ; 2020.
Abstract
COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals.
DOI: 10.1097/FTD.0000000000000761
PubMed: 32304488
Affiliations:
- Belgique, France, Italie, Norvège, Pays-Bas, États-Unis
- Hollande-Méridionale, Minnesota, Pennsylvanie, Province du Brabant wallon, Région Bretagne, Région wallonne, Østlandet
- Leyde, Louvain-la-Neuve, Oslo, Pittsburgh, Rennes, Rotterdam
- Université catholique de Louvain, Université de Pittsburgh
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32304488Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.</title><author><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name><affiliation wicri:level="4"><nlm:affiliation>Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, pharmacogenomics and pharmacokinetics (PMGK).</nlm:affiliation><orgName type="university">Université catholique de Louvain</orgName><country>Belgique</country><placeName><settlement type="city">Louvain-la-Neuve</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province du Brabant wallon</region></placeName></affiliation></author><author><name sortKey="Langman, Loralie J" sort="Langman, Loralie J" uniqKey="Langman L" first="Loralie J" last="Langman">Loralie J. Langman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Hesselink, Dennis A" sort="Hesselink, Dennis A" uniqKey="Hesselink D" first="Dennis A" last="Hesselink">Dennis A. Hesselink</name><affiliation wicri:level="3"><nlm:affiliation>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Bergan, Stein" sort="Bergan, Stein" uniqKey="Bergan S" first="Stein" last="Bergan">Stein Bergan</name><affiliation wicri:level="3"><nlm:affiliation>Oslo University Hospital, Department of Pharmacology, Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Oslo University Hospital, Department of Pharmacology, Oslo</wicri:regionArea><placeName><settlement type="city">Oslo</settlement><region nuts="2">Østlandet</region></placeName></affiliation></author><author><name sortKey="Moes, Dirk Jan A R" sort="Moes, Dirk Jan A R" uniqKey="Moes D" first="Dirk Jan A R" last="Moes">Dirk Jan A R. Moes</name><affiliation wicri:level="3"><nlm:affiliation>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Molinaro, Mariadelfina" sort="Molinaro, Mariadelfina" uniqKey="Molinaro M" first="Mariadelfina" last="Molinaro">Mariadelfina Molinaro</name><affiliation wicri:level="1"><nlm:affiliation>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Venkataramanan, Raman" sort="Venkataramanan, Raman" uniqKey="Venkataramanan R" first="Raman" last="Venkataramanan">Raman Venkataramanan</name><affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name><affiliation wicri:level="3"><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32304488</idno><idno type="pmid">32304488</idno><idno type="doi">10.1097/FTD.0000000000000761</idno><idno type="wicri:Area/PubMed/Corpus">000039</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000039</idno><idno type="wicri:Area/PubMed/Curation">000039</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000039</idno><idno type="wicri:Area/PubMed/Checkpoint">000339</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000339</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.</title><author><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name><affiliation wicri:level="4"><nlm:affiliation>Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, pharmacogenomics and pharmacokinetics (PMGK).</nlm:affiliation><orgName type="university">Université catholique de Louvain</orgName><country>Belgique</country><placeName><settlement type="city">Louvain-la-Neuve</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province du Brabant wallon</region></placeName></affiliation></author><author><name sortKey="Langman, Loralie J" sort="Langman, Loralie J" uniqKey="Langman L" first="Loralie J" last="Langman">Loralie J. Langman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Hesselink, Dennis A" sort="Hesselink, Dennis A" uniqKey="Hesselink D" first="Dennis A" last="Hesselink">Dennis A. Hesselink</name><affiliation wicri:level="3"><nlm:affiliation>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Bergan, Stein" sort="Bergan, Stein" uniqKey="Bergan S" first="Stein" last="Bergan">Stein Bergan</name><affiliation wicri:level="3"><nlm:affiliation>Oslo University Hospital, Department of Pharmacology, Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Oslo University Hospital, Department of Pharmacology, Oslo</wicri:regionArea><placeName><settlement type="city">Oslo</settlement><region nuts="2">Østlandet</region></placeName></affiliation></author><author><name sortKey="Moes, Dirk Jan A R" sort="Moes, Dirk Jan A R" uniqKey="Moes D" first="Dirk Jan A R" last="Moes">Dirk Jan A R. Moes</name><affiliation wicri:level="3"><nlm:affiliation>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Molinaro, Mariadelfina" sort="Molinaro, Mariadelfina" uniqKey="Molinaro M" first="Mariadelfina" last="Molinaro">Mariadelfina Molinaro</name><affiliation wicri:level="1"><nlm:affiliation>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Venkataramanan, Raman" sort="Venkataramanan, Raman" uniqKey="Venkataramanan R" first="Raman" last="Venkataramanan">Raman Venkataramanan</name><affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name><affiliation wicri:level="3"><nlm:affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author></analytic><series><title level="j">Therapeutic drug monitoring</title><idno type="eISSN">1536-3694</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32304488</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-3694</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Therapeutic drug monitoring</Title><ISOAbbreviation>Ther Drug Monit</ISOAbbreviation></Journal><ArticleTitle>Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/FTD.0000000000000761</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of immunosuppressive drugs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining immunosuppressive drug concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">With the present manuscript, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elens</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, pharmacogenomics and pharmacokinetics (PMGK).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université catholique de Louvain (UCLouvain), Institut de Recherche Expérimentale et Clinique (IREC), Louvain center for toxicology and applied pharmacology (LTAP).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langman</LastName><ForeName>Loralie J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hesselink</LastName><ForeName>Dennis A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rotterdam Transplant Group.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergan</LastName><ForeName>Stein</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oslo University Hospital, Department of Pharmacology, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moes</LastName><ForeName>Dirk Jan A R</ForeName><Initials>DJAR</Initials><AffiliationInfo><Affiliation>Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinaro</LastName><ForeName>Mariadelfina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Policlinico San Matteo, Clinical and Experimental Pharmacokinetics Lab, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkataramanan</LastName><ForeName>Raman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Pittsburgh, School of Pharmacy and Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail) - UMR_S 1085, F-35000 Rennes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ther Drug Monit</MedlineTA><NlmUniqueID>7909660</NlmUniqueID><ISSNLinking>0163-4356</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32304488</ArticleId><ArticleId IdType="doi">10.1097/FTD.0000000000000761</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li><li>France</li><li>Italie</li><li>Norvège</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Hollande-Méridionale</li><li>Minnesota</li><li>Pennsylvanie</li><li>Province du Brabant wallon</li><li>Région Bretagne</li><li>Région wallonne</li><li>Østlandet</li></region><settlement><li>Leyde</li><li>Louvain-la-Neuve</li><li>Oslo</li><li>Pittsburgh</li><li>Rennes</li><li>Rotterdam</li></settlement><orgName><li>Université catholique de Louvain</li><li>Université de Pittsburgh</li></orgName></list><tree><country name="Belgique"><region name="Région wallonne"><name sortKey="Elens, Laure" sort="Elens, Laure" uniqKey="Elens L" first="Laure" last="Elens">Laure Elens</name></region></country><country name="États-Unis"><region name="Minnesota"><name sortKey="Langman, Loralie J" sort="Langman, Loralie J" uniqKey="Langman L" first="Loralie J" last="Langman">Loralie J. Langman</name></region><name sortKey="Venkataramanan, Raman" sort="Venkataramanan, Raman" uniqKey="Venkataramanan R" first="Raman" last="Venkataramanan">Raman Venkataramanan</name></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Hesselink, Dennis A" sort="Hesselink, Dennis A" uniqKey="Hesselink D" first="Dennis A" last="Hesselink">Dennis A. Hesselink</name></region><name sortKey="Moes, Dirk Jan A R" sort="Moes, Dirk Jan A R" uniqKey="Moes D" first="Dirk Jan A R" last="Moes">Dirk Jan A R. Moes</name></country><country name="Norvège"><region name="Østlandet"><name sortKey="Bergan, Stein" sort="Bergan, Stein" uniqKey="Bergan S" first="Stein" last="Bergan">Stein Bergan</name></region></country><country name="Italie"><noRegion><name sortKey="Molinaro, Mariadelfina" sort="Molinaro, Mariadelfina" uniqKey="Molinaro M" first="Mariadelfina" last="Molinaro">Mariadelfina Molinaro</name></noRegion></country><country name="France"><region name="Région Bretagne"><name sortKey="Lemaitre, Florian" sort="Lemaitre, Florian" uniqKey="Lemaitre F" first="Florian" last="Lemaitre">Florian Lemaitre</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000339 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000339 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32304488
|texte= Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32304488" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |